Study PI3K as a Key Target in Glioblastoma

Time: 2:15 pm
day: Day Two


  • Explore opportunities and challenges associated with modulating PI3K
    as a therapeutic strategy in glioblastoma
  • Examine The significance of biomarkers in patient selection
  • Review emerging clinical data from paxalisib, a brain penetrant PI3K /
    mTOR inhibitor